Deregulation of protein tyrosine kinase (PTK) activity is implicated in various proliferative
conditions. Multi-target tyrosine kinase inhibitors (TKIs) are increasingly used for the …

Abstract Purpose of Review The immunosuppressive agent cyclosporine was first reported
to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 …

Despite growing interest in the relationship between autophagy and systemic metabolism,
how global changes in autophagy affect metabolism remains unclear. Here we show that …

Imatinib was the first targeted tyrosine kinase inhibitor to be approved for clinical use and
remains first-line therapy for Philadelphia chromosome (Ph+)-positive chronic myelogenous …

Sunitinib is a promising drug for clinical applications; however, the efficacy is reduced by the
feedback activation of many signaling cascades. In this study, we investigated the ability of …

A tyrosine kinase inhibitor Imatinib (IM) is used in the treatment of different varieties of
cancers. The current study was designed to explore the beneficial role of l-carnitine against …

Translation factor eIF5A participates in protein synthesis at the stage of polypeptide chain
elongation. Two eIF5A isoforms are known that are encoded by related genes whose …

It has been proposed that antidiabetic drugs, such as metformin and imatinib, at least in part,
promote improved glucose tolerance in type 2 diabetic patients via increased production of …

The present study was undertaken to assess the effect of imatinib mesylate; a tyrosine
kinase inhibitor and a well-known anticancer with numerous medical benefits on blood …

Tyrosine kinase inhibitors (TKI) interfere with glucose metabolism. Contrasting effects have
been reported, even for a given molecule. Hyperglycemia rates range between 15 and 40%; …